Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols / Benign Breast Disease/DCIS Team Project
Team Project

Benign Breast Disease/DCIS Team Project

A.   Paul Cairns (DNA Methylation Sensitivity in IBC) MAL          RASSF IA       CTGF          HIN1          APC          RAR          GSTP1       IGFBP3       GOS2          B.   Andrew Godwin (Protein Biomarker) C.   Indra Poola (Protein Biomarker) MMP-1 CEA CAM6 HYAL-1 D.   Nicole Urban CAV-1 (Caveolin 1) FN-1 (fibronectin) COL1A1 TIMP4 SPP1 (osteopontin) S100A7 (Psoriasin) MMP10 MMP12
Other, Specify
Breast and Gynecologic Cancers Research

To identify women diagnosed with atypical ductal hyperplasia (ADH) who are at increased risk of developing invasive breast cancer (IBC) and who might benefit from risk reduction with the use of chemoprevention agents such as Tamoxifen. (Note: A companion protocol will study women with DCIS and their risk for invasive breast cancer.)

Biomarkers expressed in benign breast disease tissue of women who progresse to invasive breast cancer are quantitatively and/or qualitatively different from those expressed in tissue of matched women who do not progress to invasive breast cancer. A nested case-control design will be used to determine if available proteomic and methylation biomarkers predict risk for future invasive cancer (IBC). Women with ADH who are disease-free will be matched 2:1 to women with ADH who progress to IBC.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.